Abstract 3407
Background
Few studies have directly investigated the differential expression of miRNA between low-tobacco and high-tobacco exposed HNSCC. The purpose of this study is to screen the differentially expressed miRNA and to investigate the clinical significance and potential biological mechanisms in above two groups of HNSCC.
Methods
The HNSCC datasets were obtained from TCGA database. Meanwhile, we collected 22 HNSCC patients in our hospital. The differentially expressed miRNAs between low-tobacco and high-tobacco exposed HNSCC were identified based on log2FC > 1 and FDR < 0.05. KM survival analysis, Cox regression, chi-square test were used to evaluate the clinical significance of miRNA. The correlation between gene and clinical characteristic was analyzed by WGCNA. TargetScan, miRDB, DIANA databases were used to predict the target genes of miRNA. RT-qPCR was used to identify miRNA expression in HNSCC tissues. p < 0.05 was considered statistically significant.
Results
30 differentially expressed miRNAs were identified between low-tobacco and high-tobacco exposed HNSCC. The patients with high expression of miR-499a had lower overall survival than those with low expression of miR-499a in high-tobacco exposed HNSCC (p = 0.02). Multivariate Cox regression showed that high expression of miR-499a was an independent risk factor for prognosis of high-tobacco exposed HNSCC (HR = 3.26, p = 0.03). Chi-square test showed that miR-499a was related to N stage in high-tobacco exposed HNSCC (p < 0.01). The clinical significance of miR-499a was not found in low-tobacco exposed HNSCC. WGCNA identified genes associated with N stage in high-tobacco exposed HNSCC. The three databases predicted the target genes of miR-499a, which intersected the genes associated with N stage. ZNRF1, AEBP2, NUS1 were obtained. RT-qPCR showed that miR-499a was differentially expressed between low-tobacco and high-tobacco exposed HNSCC in our own patients.
Conclusions
30 differentially expressed miRNAs are identified between low-tobacco and high-tobacco exposed HNSCC. In high-tobacco exposed HNSCC, highly expressed miR-499a may promote lymph node metastasis by down-regulating one or more of ZNRF1, AEBP2, NUS1, resulting in shortened patient survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract